GSGilberto Sánchez-González

Gilberto Sánchez-González

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gilberto Sánchez-González has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Economic Impact of Dengue Virus in Mexico Over One Decade: A Systematic Literature Review (2010–2020)

    by Gilberto Sánchez‐González, Luz del C. Hernández‐Hernández, Elaine Gallagher

    Background: Dengue is a major mosquito‐borne viral disease worldwide, imposing significant healthcare burden on governments in countries where it is endemic, such as Mexico. This systematic review focused on studies reporting the cost of dengue in Mexico during 2010–2020. To the best of our knowledge, this is the first review discussing this topic in Mexico. We analysed all published direct costs associated with care, prevention, and surveillance, as well as indirect costs. Methods: A comprehensive online search was conducted using Embase, MEDLINE, Evidence‐Based Medicine Reviews, SciELO, and LILACS. Articles reporting cost data published during 2010–2020 in English and Spanish were included. Reports from the National Ministry of Health and grey literature during the same period were also reviewed. Following the PICOS (Population, Intervention, Comparison, Outcome and Study design) framework, articles reporting direct and indirect costs were included. The National Health Service Wales tool was used to assess the quality of the studies included. Results: Seven articles fulfiled the inclusion criteria. All articles reported the nationwide cost of dengue, and three focused on specific Mexican states. The dengue‐related economic burden was substantial, peaking in 2013, with annual costs of $176.82 million (adjusted present value, $281.60 million). All the searches were verified in January 2023. Conclusions: The economic burden of dengue in Mexico is high and is further impacted by outbreaks, resulting in significant costs to the healthcare system and productivity losses. The heterogeneity of the methodological approaches in the cost studies reviewed makes it a challenge to compare them.

  • Open Access

    Estimation of populations at risk for severe influenza and vaccination coverage in Mexico, 2010–2021

    by Arturo Galindo-Fraga, Gerardo Luna-Casas, Ricardo Gasca-Pineda, Gilberto Sánchez-González

    Background: Influenza remains an important cause of morbidity among populations with underlying medical conditions associated with increased risk of severe disease. This study aimed to estimate the size of populations eligible for influenza vaccination according to the Mexican Universal Vaccination Program and to evaluate vaccination coverage gaps among populations at risk in Mexico between 2010 and 2021. Methods: A retrospective analytical study was conducted using epidemiological and administrative healthcare databases from Mexican public healthcare institutions. Population estimates were constructed using prevalence-based epidemiological projections, healthcare system records, and attended patient data from populations at risk. Descriptive analyses and time-series modeling were performed to evaluate vaccination coverage patterns and healthcare demand over time. Results: Across all analyzed populations at risk, the number of individuals receiving healthcare services was consistently lower than the number of notified cases and substantially lower than prevalence-based epidemiological estimates. Vaccination coverage varied considerably across populations at risk and remained incomplete throughout the study period. In 2021, although approximately 12.5 million influenza vaccine doses were administered among populations at risk, a substantial proportion of potentially eligible individuals remained unvaccinated. Forecasting analyses suggested a progressive increase in healthcare demand among populations at risk over time. Conclusions: Important gaps persist between the estimated population at risk, diagnosed individuals, healthcare utilization, and influenza vaccination coverage in Mexico. The analytical framework proposed in this study integrates epidemiological prevalence estimates, healthcare utilization patterns, and vaccination data to identify unmet vaccination needs and may support improved public health planning, prioritization strategies, and strengthening of influenza vaccination programs in Mexico and similar settings.

  • Open Access

    Stochastic epidemiological model: Simulations of the SARS-CoV-2 spreading in Mexico

    by Pablo Carlos López Vázquez, Gilberto Sánchez González, Jorge Martínez Ortega, Renato Salomón Arroyo Duarte

    In this paper we model the spreading of the SARS-CoV-2 in Mexico by introducing a new stochastic approximation constructed from first principles, where the number of new infected individuals caused by a single infectious individual per unit time (a day), is a random variable of a time-dependent Poisson distribution. The model, structured on the basis of a Latent-Infectious-(Recovered or Deceased) (LI(RD)) compartmental approximation together with a modulation of the mean number of new infections (the Poisson parameters), provides a good tool to study theoretical and real scenarios.

  • Open Access

    Burden of disease and associated complications of hepatitis a in children and adults in Mexico: A retrospective database study

    by Adriana Guzman-Holst, Gerardo Luna-Casas, Ana Burguete Garcia, Vicente Madrid-Marina, Maria Yolanda Cervantes-Apolinar, Anar Andani, Gloria Huerta-Garcia, Gilberto Sánchez-González

    Background: Hepatitis A virus (HAV) infection is a leading cause of viral hepatitis in children, yet the HAV vaccine is not included in the national immunization program (NIP) in Mexico. This study addresses an identified evidence gap of the burden of hepatitis A disease, complications, and associated costs in Mexico by analyzing surveillance and healthcare data. Data review included disease morbidity (incidence and hospitalization), mortality, and healthcare resource utilization costs. Methods: In this observational, retrospective database study, we conducted a systematic screening, extraction, and analysis of outcome data from the national surveillance system in Mexico from January 2000 to December 2019. Results: During the analysis period (2000–2019), the average incidence rate/year of HAV cases was 14.7 (5.4–21.5) per 100,000 inhabitants. Children 1–9 years of age (YoA) had the highest average incidence rate/year with 47.8 (14.7–74.5). The average hospitalization rate/year due to HAV infection was 5.8% (2.9–9.6%). Although the highest burden of HAV continued to be in children (1–9 YoA), an increase in incidence and hospitalizations (with complications) in older age groups (≥ 10–64 YoA) was observed. The annual average fatality rate was estimated to be 0.44% (0.26–0.83%) of which 28.8% of deaths were concentrated in adults ≥ 65 YoA. The total direct costs of medical attention due to HAV and related complications were estimated at $382 million Mexican pesos. Conclusion: The overall results suggest an uptrend in HAV infections in adolescents/adults compared to children in Mexico. Therefore, as the overall incidence risk of HAV infection decreases, the mean age of infection increases. This consequently increases the risk of severity and complications in older age groups, thus increasing the demand for healthcare resources. Our findings provide evidence for including the inactivated HAV vaccine in the Mexican NIP.


  • Open Access

    Pertussis infant morbidity and mortality trends after universal maternal immunisation in Mexico: An ecological database study with time-series analysis

    by Adriana Guzman-Holst, Gerardo Luna-Casas, Maria Y. Cervantes-Apolinar, Gloria C. Huerta-Garcia, Patricia Juliao, Gilberto Sánchez-González


  • Open Access

    New Genotype Emergence of DENV are Constrained by the Double Host Selection, Reducing the Probability of Alternative Serotype Emergence

    by Gilberto Sánchez-González, Renaud Conde

    Since their discovery and sequencing 40 years ago, the DENV genotypes have shown an extreme coherence regarding the serotype class they code for. Considering the RNA virus mutation rate, we used Timed Markov Model to explore the transmission possibilities of mutated viruses and the statistical eventualities of new serotype emergence. We find that around 1 000 years are required for a new serotype to emerge, in line with phylogenetic analysis of the Dengue serotypes. Our work provides a mechanistic explanation of the strictness and low probability of a new Dengue virus serotype occurrence. Author summary: Recent Dengue virus global spread has drawn the attention of the Public Health Policy makers in developing countries and developed countries as well. The infection gravity and the hemorrhagic dengue syndromes have been related with the absence or presence of previous DENV immunity. Therefore, the emergence of a new DENV serotype and its spread constitute a matter of concern. Here, we constructed a mathematical model to determine the probability of such event, as well as de-entangle the mechanistic reasons behind the low serotype emergence factor of the DENV.

  • Open Access

    Vaccine coverage and compliance in Mexico with the two-dose and three-dose rotavirus vaccines

    by Gerardo Luna-Casas, Patricia Juliao, Roberto Carreño-Manjarrez, Andrés Castañeda-Prado, Maria Yolanda Cervantes-Apolinar, Ricardo Navarro-Rodriguez, Gilberto Sánchez-González, Ricardo Cortés-Alcalá, Rodrigo DeAntonio

    Worldwide, rotavirus infection has been a leading cause of severe diarrhea morbidity and mortality. Two rotavirus vaccines have been used in the National Immunization Program (NIP) in Mexico; two-dose Rotarix from 2006 to 2011 and three-dose RotaTeq since 2011. This study assessed coverage (receiving at least one dose or full dose series) in eligible infants, compliance (% completing dose series and % completing series on schedule) in eligible infants vaccinated with Rotarix (2010) versus RotaTeq (2012), using Mexican Social Security Institute data nationwide and by regions. In 2010, 80.7% received at least one dose of Rotarix, 75.6% received both doses and 57.0% received both doses on schedule. In 2012, 85.7% received at least one dose of RotaTeq, 61.0% received all three doses and 43.2% received all three doses on schedule. More eligible infants received all doses with Rotarix versus RotaTeq (p < 0.001). Among infants vaccinated with Rotarix versus RotaTeq, 93.7% versus 71.1% completed full series (p < 0.001), and 75.5% versus 70.9% completed full series on schedule (p = 0.105), respectively. The full series coverage and compliance decreased in all regions with RotaTeq compared with Rotarix. In conclusion, rotavirus vaccination has successfully reduced morbidity and mortality in children under 5 years in Mexico. This study found significant differences in full series coverage and compliance among infants and a higher proportion of completed scheduled at an earlier age in Mexico when comparing a two-dose vaccine in 2010 with a three-dose vaccine in 2012. Such differences might need to be taken into consideration to maximize NIP benefits, including early protection of the rotavirus vaccination program.


  • Open Access

    Prediction of dengue outbreaks in Mexico based on entomological, meteorological and demographic data

    by Gilberto Sánchez-González, Renaud Condé, Raúl Noguez Moreno, P C López Vázquez

    Dengue virus has shown a complex pattern of transmission across Latin America over the last two decades. In an attempt to explain the permanence of the disease in regions subjected to drought seasons lasting over six months, various hypotheses have been proposed. These include transovarial transmission, forest reservoirs and asymptomatic human virus carriers. Dengue virus is endemic in Mexico, a country in which half of the population is seropositive. Seropositivity is a risk factor for Dengue Hemorrhagic Fever upon a second encounter with the dengue virus. Since Dengue Hemorrhagic Fever can cause death, it is important to develop epidemiological mathematical tools that enable policy makers to predict regions potentially at risk for a dengue epidemic. We formulated a mathematical model of dengue transmission, considering both human behavior and environmental conditions pertinent to the transmission of the disease. When data on past human population density, temperature and rainfall were entered into this model, it provided an accurate picture of the actual spread of dengue over recent years in four states (representing two climactic conditions) in Mexico.


  • The cost-effectiveness of treating triple coinfection with HIV, tuberculosis and hepatitis C virus

    by G Sánchez-González

    It is known that treating patients with HIV who are coinfected with TB or HCV implies high cost and low efficacy, but it is possible that the population with triple infections could achieve important benefits in terms of years of life gained.


  • Open Access

    Cost-Effectiveness of Blood Donation Screening for Trypanosoma cruzi in Mexico

    by Gilberto Sánchez-González, Alejandro Figueroa-Lara, Miguel Elizondo-Cano, Leslie Wilson, Barbara Novelo-Garza, Leopoldo Valiente-Banuet, Janine M. Ramsey

    An estimated 2 million inhabitants are infected with Chagas disease in Mexico, with highest prevalence coinciding with highest demographic density in the southern half of the country. After vector-borne transmission, Trypanosoma cruzi is principally transmitted to humans via blood transfusion. Despite initiation of serological screening of blood donations or donors for T. cruzi since 1990 in most Latin American countries, Mexico only finally included mandatory serological screening nationwide in official Norms in 2012. Most recent regulatory changes and segmented blood services in Mexico may affect compliance of mandatory screening guidelines. The objective of this study was to calculate the incremental cost-effectiveness ratio for total compliance of current guidelines from both Mexican primary healthcare and regular salaried worker health service institutions: the Secretary of Health and the Mexican Institute for Social Security. We developed a bi-modular model to analyze compliance using a decision tree for the most common screening algorithms for each health institution, and a Markov transition model for the natural history of illness and care. The incremental cost effectiveness ratio based on life-years gained is US$ 383 for the Secretary of Health, while the cost for an additional life-year gained is US$ 463 for the Social Security Institute. The results of the present study suggest that due to incomplete compliance of Mexico’s national legislation during 2013 and 2014, the MoH has failed to confirm 15,162 T. cruzi infections, has not prevented 2,347 avoidable infections, and has lost 333,483 life-years. Although there is a vast difference in T. cruzi prevalence between Bolivia and Mexico, Bolivia established mandatory blood screening for T.cruzi in 1996 and until 2002 detected and discarded 11,489 T. cruzi -infected blood units and prevented 2,879 potential infections with their transfusion blood screening program. In the first two years of Mexico’s mandated program, the two primary institutions failed to prevent due to incomplete compliance more potential infections than those gained from the first five years of Bolivia’s program. Full regulatory compliance should be clearly understood as mandatory for the sake of blood security, and its monitoring and analysis in Mexico should be part of the health authority’s responsibility. Chagas disease continues to be a neglected disease in Mexico and Latin-American. Although an estimated 96% of Trypanosoma cruzi transmission to humans occurs via 32 triatomine vector species, the only transmission prevention in Mexico has been sparse and based on heterogeneous blood donation screening. Despite mandating serological screening of blood donations or donors for T. cruzi since 1990 in most Latin American countries, Mexico only finally included mandatory serological screening nationwide in official Norms in 2012. In 2005, a survey of blood donor centers in Mexico was conducted to compare T. cruzi prevalence in donations with that of Mexican migrants in the US. Since there was little coincidence between data from that survey and official screening or confirmed case rates, and screening for the social security system only initiated in 2010, the objective of this study was to calculate the incremental cost-effectiveness ratio for total compliance of current guidelines from both Mexican primary healthcare (the Secretary of Health) and regular salaried worker health services (the Mexican Institute for Social Security). A bi-modular model to analyze compliance was developed using a decision tree for the most common documented screening algorithms for the two principal health institution, and a Markov transition model for the natural history of illness and care. The incremental cost effectiveness ratio based on life-years gained is US$ 383 for the Secretary of Health (MoH), while the cost for an additional life-year gained is US$ 463 for the Social Security Institute (IMSS). Using survey compliance data for MoH, and that published by IMSS, failure to detect current infections, to avoid new infections, and life-years lost were calculated for 2013 and 2014 for both institutions. The MoH has failed to confirm 15,162 T. cruzi infections, did not prevent 2,347 avoidable infections, and lost 333,483 life-years over the two year period. Full regulatory compliance should be mandatory and timely monitoring should be part of the health authority’s responsibilities for the sake of blood security in Mexico.